Four new angucyclin(on)es, 11-deoxylandomycinone (1) and landomycins X-Z (2-4) were isolated from the crude extract of Streptomyces cyanogenus K62 mutant strain, along with the recently reported landomycins S, T and V (5-7) and five other known compounds. The structures of the new compounds 1-4 were elucidated by 1D and 2D NMR studies along with HR-MS analyses. Unique about the structures is that the fourth sugar moiety (sugar D) in landomycins X-Z (2-4) was b-D-amicetose instead of b-D-olivose, usually found in this position. The new angucyclin(on)es were biologically evaluated in comparison with previously known congeners against a small panel of MCF-7 (estrogen responsive) and MDA 231 (estrogen refractory) breast cancer cell lines. 11-deoxylandomycinone (IC 50 2.1 ± 0.3 and 1.2 ± 0.4 lM) and landomycin Y (IC 50 1.0 ± 0.1 and 2.0 ± 0.1 lM) showed the highest cytotoxic potencies against both the cell lines.
INTRODUCTION
The landomycins are a subgroup of the large family of angucycline group antibiotics, which are characterized by diverse biological activities, such as antitumor, antibacterial and enzyme inhibition. [1] [2] [3] [4] [5] [6] [7] The chemical structures of the landomycins consist of a polyketide-derived angucyclinone decorated with a single deoxyoligosaccharide chain of various lengths. Landomycins A-D (C, 13) were originally found as products of Streptomyces cyanogenus S136. 3, 5, 6 Later, several more landomycins were discovered, and analyzed for their structure-activity relationships. [8] [9] [10] [11] [12] It was found that the biological activities were mainly dependent on the length of the saccharide chain, with those analogs possessing longer saccharide chains, being more potent in general. 10, 13, 14 Landomycin A, the principal product of S. cyanogenus S136, is the most potent antitumor agent, possessing an unusual spectrum of activity against the NCI 60 human cancer cell line panel. 1, 2, 6 It contains a hexasaccharide side chain, constructed from two repeating trisaccharide patterns (D-olivose-4-1-D-olivose-3-1-Lrhodinose). Except for landomycin C (13), the sugar chains of all reported landomycins are constructed solely from L-rhodinose and D-olivose units. Landomycin C (13) was the only analog that bears three different sugar moieties; D-olivose, L-rhodinose and D-amicetose.
During our search for further new cytotoxic landomycin analogs, a fermentation of S. cyanogenus K62 in SG-medium was carried out which afforded four new angucyclin(on)es: 11-deoxylandomycinone (1) and landomycins X-Z (2-4) along with the known compounds tetrangulol (11) , tetrangomycin (12) , landomycins M (8), F (9) and O (10). 10, 11, [15] [16] [17] In addition, we also found again the very recently reported landomycins S, T and V (5-7) (Scheme 1). 12 
RESULTS AND DISCUSSION
In our search for new landomycin analogs with altered saccharide patterns we screened the regulator-affected high producing mutants S. cyanogenus K62 and S. cyanogenus K60. 18 The production spectrum using SG-medium was very similar for both mutant strains, based on the TLC and HPLC-MS analyses (Supplementary Figure S1) . However, the general production yields of S. cyanogenus K62 were significantly higher than those of S. cyanogenus K60. Therefore, we focused on the K62 mutant for the search of new minor congeners.
A pre-culture of S. cyanogenus K62 served to cultivate 40 of 0.25 L-Erlenmeyer flasks each containing 100 ml of SG-medium, on rotary shaker for 3 days. The broth was harvested, mixed with celite, filtered off and extracted with ethyl acetate, and the organic extracts from supernatant and cells were concentrated in vacuo to afford 6.45 g of a reddish powder crude extract (1.61 g l À1 ). A TLC analysis of the strain extract exhibited several UV orange-red fluorescent bands at 366 nm, which turned blue on treatment with 2 N NaOH, as indicative of perihydroxy quinones. The HPLC-MS analysis of the crude extract displayed several components with UV spectrum characteristic of 11-deoxylandomycin chromophores, which were likely new congeners (Supplementary Figures S4 and S5 ). 12 Working up and purification of 0.97 g from the strain extract using various chromatographic techniques ( Figure 1 ) led to the isolation of four new compounds; 11-deoxylandomycinone (1) and landomycins X-Z (2-4), all three possessing 11-deoxyaglycone moiety. In addition, eight known compounds; tetrangulol (11) , tetrangomycin (12) , landomycins M, F and O (8-10) were isolated along with the recently reported landomycins S, T and V (5-7).
Structure elucidation
Compound 1 was obtained as an orange amorphous powder. The molecular formula of 1 was determined by high resolution electrospray ionization mass spectrometry (HRESIMS) as C 19 H 14 O 5 (Tables 1 and 2 ). The proton NMR spectrum of 1 displayed two broad singlets at d 12.07 and 9.75, representing peri-hydroxy groups, and a 1,2,3-trisubstituted aromatic moiety revealed by an ABC system in the region of d 7.73B7.32 (J¼7.5B8.8 Hz, Table 3 ). Two additional broad aromatic signals, each 1H, at d 6.64 and 6.57 showed another highly substituted aromatic ring with two m-coupled aromatic protons. The aliphatic region revealed an oxymethine signal (d 5.03) directly next to a methylene group (d 2.89 and 2.76; d, J¼16.2B16.2 Hz), which was confirmed by a H,H-COSY experiment (Figure 2 ). Furthermore, a singlet of an aromatic-bound methyl group was observed at d 2.26. All these structural features are typical for 11-deoxylandomycinone. The 13 C NMR/hetero single quantum coherence (HSQC) spectra (Table 4) confirmed compound 1 to be 11-deoxylandomycinone, and showed the quinone carbonyls (d 188.0 and 183.7), the small DdB4 p.p.m.
indicating both carbonyls to be chelated with hydroxyl groups. In the sp 3 region, the three expected carbon signals representing an oxymethine carbon (d 57.1), methylene (d 36.5) and one methyl (d 21.2) groups, were observed. Finally, the HMBC spectrum (Figure 2 ) of compound 1 showing 3 J correlations between H-11 and C-12, and between H-6 and C-7, confirmed structure 1 as 11-deoxylandomycinone, with C-6 being R-configured, as it displayed the same coupling constants and NOESY correlations ( Figure 2 and Table 3 ) typically of all reported landomycins. A data base search (Chemical Abstracts) confirmed the novelty of structure 1.
Compound 2 was obtained as orange solid, with a molecular weight of 1054 Da corresponding to a molecular formula of C 55 H 74 O 20 , as deduced by HRESIMS (Tables 1 and 2 ). The proton NMR spectrum (Table 3 ) and the 13 C NMR/HSQC spectra ( (Tables 3 and 4 and Figure 3 ) are in full agreement with structure 2. The relative configurations of the sugar residues were derived from the coupling constants and NOESY experiments (Figure 4 ) indicating that compound 2 has the same stereochemistry both at C-6 of the aglycone and the hexasaccharide sugar moieties as found previously for landomycin C (13). In sum, structure 2 was determined to be 11-deoxylandomycin C, and was named landomycin X.
Closely related to landomycin X (2), compound 3 was obtained as dark red solid from the same fraction III, exhibiting a molecular Figures 5 and 6 ). Therefore, structure 3 was determined as 5,6-anhydro-landomycin X, and consequently named landomycin Y. Structurally related to landomycin X (2) and the recently reported landomycin V (7) 12 , compound 4 was obtained as orange solid, with a molecular formula of C 49 H 64 O 18 (HREIMS); that is, by 16 amu smaller than landomycin V (7), for physico-chemical properties see Tables 1 and 2 . Comparison of the 1 H NMR data of compound 4 with those of landomycin X (2) revealed that the terminal a-L-rhodinose moiety was missing, whereas the aglycone was identical to the one Table 4 13 C NMR data of 11-deoxylandomycinone and landomycins X-Y (2, 3) compared with the reported data of landomycin C (13), 6 (d C , mult) Table 3 ). Thus, compound 4 was identified as 3D-deoxy-landomycin V, and consequently named landomycin Z.
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Biological activity
The anticancer activity of the new angucyclin(on)es 1-4 compared with landomycin A were determined using MCF-7 (estrogen responsive) and MDA 231 (estrogen refractory) breast cancer cells (Table 5) . Cell viability assays showed that compounds 1-4 and landomycin A have comparable anticancer activities against both cells lines. Specifically, against MCF-7 cells, compound 3 was the most potent (IC 50 ¼1.0 mM), but also compounds 1, 2 and 4 appear to have comparable activity (IC 50 ¼2.1, 2.8 and 2.6 mM, respectively) to landomycin A. 11-deoxylandomycinone (1) (IC 50 ¼1.2 mM) was the most potent compound against MDA 231 cells. However compounds 2-4, (IC 50 ¼2.0, 2.0 and 2.5 mM, respectively) also displayed significant cytotoxic activities, again comparable to landomycin A. In conclusion, unlike some of the previously discovered new 11-deoxy-landomycins; for example, landomycins F (9), M (8), S (5), T (6) and V (7), the new angucylin(on)es 1-4 showed potency against both MDA 231 and MCF-7 cells, previously only found for landomycin A and other landomycins bearing an 11-OH group. The exchange of the fourth sugar moiety (b-D-olivose) of landomycins S, T and V (5-7) with b-Damicetose as in the new landomycins X-Z (2-4) slightly improve the anticancer activity (Table 5 ). The results suggest that a missing 4D-OH group; that is, substitution of D-olivose by a D-amicetose unit in 11-Deoxylandomycinone and landomycins X-Z KA Shaaban et al D-position of the saccharide chain, is advantageous, showing that subtle changes in the H-bonding properties of the saccharide chains can have a significant effect. As discussed before, the highest activity of landomycins X-Z (2-4) and aglycone 1 indicate that these compounds may have different mechanism-of-action, one for the aglycone alone, the other depending on the length of the sugar side chain, again with longer chains being advantageous. It should also be noted that the observed effects on estrogen receptor (ER)-negative (MDA-231) compared with ER-positive (MCF-7) breast cancer cells could be influenced by differential gene expression patterns known from these cell lines; for example, MDA-231 cells express higher cdc2, cyclin B1, cyclin D1, cyclin E, IGFBP-3, TGF-a, TGFb2 compared with MCF-7 cells. Investigations of the molecular mechanism of the landomycins are currently in progress.
EXPERIMENTAL PROCEDURE General experimental procedures
UV spectra were recorded on a Shimadzu UV-1800 (Model TCC-240A) UV spectrometer. NMR spectra were measured on a Varian VnmrJ 500 ( 1 H, 500 MHz; 13 C, 125.7 MHz) spectrometer, the d-values were referenced to the respective solvent signals. ESI mass spectra were recorded on a Finnigan LCQ ion trap mass spectrometer. Electrospray ionization high resolution mass spectra were recorded on an Agilent LC/MSD TOF (resolution: 10 000; 3 p.p.m. mass accuracy; Inlet Systems: Agilent Technologies 1200 Series LC pumps) Mass Spectrometer (Agilent, Palo Alto, CA, USA). LC/MS/MS measurements were performed on an Applied Biosystems 3200 QTRAP mass spectrometer (Applied Biosystems, Foster City, CA, USA) using electrospray ionization in the positive and negative ionization mode, inlet systems: Agilent 1100 series HPLC; Resolution: Unit mass. Samples were introduced by means a HPLC-MS analyses showed that these compounds remained stable under assay conditions, and did not decompose into aglycone and sugar residues. b NP, Not potent, the data for compounds 5-12 were taken from reference. 12 c Previously reported 10 IC 50 against MCF-7 cells was 53.2 ± 0.7 mM using a sulforhodamine B assay. d Previously reported 10 IC 50 against MCF-7 cells was 15.9 ± 3.0 mM using a sulforhodamine B assay. e Previously reported 10 IC 50 against MCF-7 cells was 46.7 ± 9.8 mM using a sulforhodamine B assay.
of a syringe pump. HPLC purifications were carried out using a Symmetry Prep C 18 10 mm column (10Â150 mm) on a binary LC system. HPLC-MS analyses were carried out using a Symmetry Anal C 18 
Cell viability assay
To determine the cytotoxic activity of the new compounds 11-deoxylandomycinone (1), landomycins X-Z (2-4) and landomycin A were tested against two breast cancer cell lines, MCF-7 (estrogen responsive) and MDA 231 (estrogen refractory). Cell viability of these two cell lines in response to the various concentrations of compounds were determined using the trypan blue exclusion assay, in which 50Â10 3 cells in 0.5 ml medium were plated in each well of a 24-well plate and allowed to attach overnight. The medium was replaced the following day with fresh medium containing different concentrations of the compounds to be tested and the plates were incubated for 24 h at 37 1C. At the end of the treatment period both adherent and floating cells were collected, and resuspended in phosphate-buffered saline for trypan blue staining using 0.4% stain for 3 min. Stained (dead) and unstained (live) cells were counted using a hemocytometer, cell viability in response to specific compounds was determined, dose-response curve was plotted and finally IC 50 was calculated. Each set of experiment was performed three times to confirm reproducibility of the results.
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